Barr gets final approval for Kytril tablets
Jan 2 (Reuters) - Barr Pharmaceuticals Inc BRL.N said its Barr Laboratories Inc unit received final approval from U.S. health regulators for its generic version of Roche Laboratories Inc's Kytril tablets. The company said it received the approval from the U.S. Food and Drug Administration following the expiration of Roche's patent on December 28, 2007. Barr plans to launch its product shortly. Kytril is prescribed to prevent nausea and vomiting related to certain types of cancer therapy. (Reporting by Anant Vijay Kala in Bangalore; Editing by Himani Sarkar)
© Thomson Reuters 2017 Tutti i diritti assegna a Reuters.